The published research record describes GHRP-6 dosing in micrograms per kilogram of body weight rather than fixed milligram amounts, a convention inherited from the controlled endocrine studies that first characterized the compound. Across that literature the peptide is handled as a lyophilized powder, reconstituted immediately before use, and given by injection under fasted or standardized-meal conditions. None of this carries FDA approval or an established human dosing label; the source material consistently discusses the compound as a research reagent, not an approved therapeutic.
Across the published literature GHRP-6 is documented as a research reagent dosed in micrograms per kilogram of body weight, most often reconstituted from lyophilized powder and injected, with no FDA-approved human dosing protocol on record.
Reported figures cluster into two families that track the route of administration. Intravenous human pharmacology work centered on single bolus doses of roughly 0.1 to 2 micrograms per kilogram, with 1 microgram per kilogram recurring as a reference challenge dose, while subcutaneous protocols report a similar or slightly higher per-kilogram band to offset slower absorption. These are experimental parameters recorded for research use only, not medically validated dosing recommendations.
| Parameter | Intravenous | Subcutaneous |
|---|---|---|
| Reported band | ~0.1 to 2 mcg/kg | Similar or slightly higher per-kg |
| Reference dose | ~1 mcg/kg | Not standardized |
| Response shape | Sharp, measurable pulse | Broader, blunted rise |
| Plateau point | ~1 mcg/kg IV, then flattens | Dose-dependent up to a point |
The literature reports intravenous GHRP-6 challenge doses of roughly 0.1 to 2 micrograms per kilogram, with about 1 microgram per kilogram cited as a reference dose beyond which the growth hormone response flattens, all recorded as research parameters rather than validated human doses.
Intravenous injection dominates the foundational work because it delivers a known quantity into circulation with essentially complete bioavailability, producing the fast, reproducible pulse suited to dose-response measurement. As protocols moved toward longer and more practical designs, subcutaneous injection became the more frequently reported route, and non-injectable routes appear only at the margins of the record.
Published GHRP-6 studies rely on intravenous injection for the cleanest measurable pulse and subcutaneous injection for repeated dosing, while intranasal delivery reports only a small fraction of injected bioavailability and oral delivery is documented as largely ineffective.
Scheduling in the literature falls along a spectrum defined by what a study is trying to measure, not by any therapeutic regimen. At one end sit single-pulse challenge tests; at the other, repeated dosing that probes whether the secretagogue effect holds up under sustained stimulation, with the administration schedule tightly coordinated to the blood-sampling schedule.
In the research record GHRP-6 scheduling ranges from single-dose challenge tests that capture one hormonal pulse to repeated once- or twice-daily administration studying desensitization, with the dosing rhythm coordinated to the blood-sampling schedule rather than to any therapeutic regimen.
Published protocols and vendor inserts describe GHRP-6 arriving as a lyophilized white powder that is stable dry but must be dissolved before any administration. The steps reported in that material document laboratory practice for a research reagent, not instructions for personal use, and they emphasize gentle handling because vigorous agitation can denature the peptide and cut potency.
Published protocols describe reconstituting lyophilized GHRP-6 with bacteriostatic or sterile water, adding the diluent gently against the vial wall and swirling rather than shaking to preserve potency, as documented laboratory practice for a research reagent rather than an approved therapeutic.
Weight-based scaling is the standard in the literature because the size of the growth hormone pulse tracks with the responsive tissue and the volume the dose distributes into, so a fixed absolute amount would over-stimulate a small subject and under-stimulate a large one. Protocols therefore state a target in micrograms per kilogram and convert it per subject, a normalization used for experimental comparability rather than clinical dosing.
Research protocols scale GHRP-6 to body weight by stating a target in micrograms per kilogram and multiplying by the subject's weight, so a 1 microgram per kilogram target in a 70 kilogram subject is recorded as 70 micrograms, a normalization used for experimental comparability rather than clinical dosing.
The literature frames GHRP-6's upper boundary less as a hard toxic threshold and more as a point of diminishing return coupled with off-target effects. The growth hormone response saturates near 1 microgram per kilogram intravenously, and higher amounts more strongly provoke cortisol and prolactin release, which the record treats as a reason escalation is discouraged rather than a demonstrated safe maximum.
The literature bounds useful GHRP-6 dosing on the high side by a growth hormone response plateau near 1 microgram per kilogram intravenously and by rising cortisol and prolactin release rather than by a demonstrated safe maximum, and the figures cited are experimental parameters, not tolerances for personal use.
The published record treats food state as a genuine experimental variable because circulating nutrients directly dampen the growth hormone pulse the peptide elicits. Elevated free fatty acids, glucose, and the insulin they trigger blunt the response, so a subject dosed shortly after eating produces a smaller and less reproducible pulse than the same subject dosed fasted, and the strongest designs pin food state down deliberately.
Because free fatty acids, glucose, and insulin blunt the growth hormone response, GHRP-6 challenge protocols in the literature commonly require an overnight fast with morning administration, or substitute a standardized meal when the fed state is the object of study, documenting food timing as a controlled experimental variable.
Potency preservation in the record hinges on the gap between the dry and the dissolved states. As a lyophilized powder the peptide holds activity for extended periods under freezing or refrigeration, but once reconstituted it grows fragile and degrades through hydrolysis and oxidation, which is why the literature describes a finite in-use window and cold, dark storage.
| Handling factor | Lyophilized powder | Reconstituted solution |
|---|---|---|
| Storage | Frozen or refrigerated, dark, dry | Refrigerated, ~2 to 8 C |
| Stability | Extended periods | Finite, commonly a few weeks |
| Main degradation risk | Moisture, light, heat | Hydrolysis, oxidation, freeze-thaw |
| Sign of loss | Moisture damage | Cloudiness or particulates |
The literature documents lyophilized GHRP-6 as stable for extended periods when kept frozen or refrigerated, while the reconstituted solution is held near 2 to 8 degrees Celsius, kept from repeated freeze-thaw cycling, and treated as unreliable after a few weeks or once cloudiness or particulates appear.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-6. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
